A Dual-Pathway Neurochemical and Neuroimaging Framework for Severe Psychiatric Disease: Stratifying Dopaminergic and Primary GABAergic Subtypes in Medication-Naive Patients
Abstract Severe neuropsychiatric conditions—including schizophrenia, bipolar mania, and catatonia—continue to be diagnosed primarily through subjective behavioral observation and treated via trial-and-error dopamine receptor blockade. While dopamine antagonists alleviate symptoms in a majority of patients, approximately 30% fail to respond, pointing to an incomplete mechanistic model. This paper proposes a strictly biological, dual-pathway hypothesis: severe psychiatric syndromes are physical brain diseases driven by two distinct, measurable neurochemical pathologies—(1) excess dopaminergic signaling, and (2) a primary deficit in inhibitory gamma-aminobutyric acid (GABA) tone, acting either independently or alongside dopamine dysregulation. Furthermore, this framework proposes that behavioral and cognitive symptoms are downstream physical outputs of underlying circuit dysfunction rather than psychological or behavioral failings. To validate this model and rule out medication-induced brain alterations, a large-scale neuroimaging protocol utilizing functional Magnetic Resonance Imaging (fMRI) and Magnetic Resonance Spectroscopy (MRS) in strictly medication-naive, first-episode patients is outlined. Accumulating baseline neurochemical and connectivity datasets across large cohorts will reveal repeating, condition-specific visual signatures—enabling blind diagnostic consensus among neurologists and psychiatrists from imaging alone, and allowing upfront stratification of the 30% non-responder group toward targeted GABAergic intervention.
Authors
- Kim R. Flinn
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.5281/zenodo.24327665
- Primary Topic
- Schizophrenia research and treatment
- Type
- preprint